藥 名
永康
柳營
佳里
|
更新日期：10/25/2018 16:34:05
CeftaZidime(1g/V)針
|
現行藥品外觀
11C120
健保
自費
|
中文名：孢妥注射劑
健保碼：AC41754209
廠 牌：生達
|
|
藥理分類
J01DD02
|
【Antibacterials for systemic use】
Third-generation cephalosporins
|
|
|
藥理作用
|
|
|
Product name
|
Cetazine(1gm/V)針.
|
|
Dosage form
|
Inj. 1g/Vial
|
|
Administration & Dosage
|
IM/IV,
【Adult】
● Cystic fibrosis: 90-150 mg/kg/day q8h (max: 6 g/d)
● Empiric therapy in immunocompromised patients: 2 g q8h
● Intra-abdominal infection, severe (in combination with metronidazole): 2g q8h for 4-7d.
● Pneumonia: * Uncomplicated: IM, IV: 1g q8h.
*Hospital-acquired or ventilator-associated: IV: 2 g q8h for 7 d
● Prosthetic joint infection, Pseudomonas aeruginosa (alternative to cefepime or meropenem): IV, 2 g q8h for 4-6 wks.
● Skin and s tissue infections: IV,IM: 1 g q8h
●Severe infections, including meningitis, CNS infection, osteomyelitis, gynecological: IV, 2 g q8h
●UTI: IV, 1-2 g q8-12h
【Pediatric】
● General dosing, susceptible infections: IM, IV: * Mild to moderate infections: 90 to 150 mg/kg/day divided q8h; max 3g/d
* Severe infections: 200 mg/kg/day divided q8h; max 6 g/d
● Cystic fibrosis, lung infection caused by Pseudomonas spp: Infants, Children, and Adolescents: IV: 150-200 mg/kg/day divided q6-8h,max 6 g/d.
|
|
建議給藥途徑
|
IM、IV推、IV滴、UF
|
|
腎功能劑量建議
|
ClCr >50：1 (or 2g if Pseudomonas spp. infection) Q8H
ClCr 10-50：1 (or 2g if Pseudomonas spp. infection) Q12H
ClCr <10：1 (or 2g if Pseudomonas spp. infection) Q24H
CVVH：2g Q12-24H
|
|
肝功能劑量建議
|
無特別標註
|
|
Contraindication
|
history of cephalosporin hypersensitivity.
|
|
Precaution
|
|
|
Adverse reaction
|
【1-10%】Pruritus, skin rash, increased lactate dehydrogenase, increased gamma-glutamyl transferase, diarrhea, eosinophilia ), positive direct Coombs test , thrombocythemia, increased ALT/AST, increased serum alkaline phosphatase, hypersensitivity, inflammation at injection site, injection site phlebitis,fever
【unknown】Seizure, agranulocytosis, leukopenia, lymphocytosis, neutropenia, thrombocytopenia, increased BUN, increased Scr.
【<1%】not referred here, please see package insert ot other reference.
|
|
Pregnancy Category
|
B / 可能安全
|
|
Notes
|
Reconstitute 1gm vial:
1. with 3ml water for inj. for IM.
2. with 10 ml water for inj. for IV push.
3. further diluted in 50 ml compatible solution for IV infusion.
|
|
相關連結
|
|
|
磨粉及剝半提示 |
無特別標註
|
|
給藥及保存方式 |
以注射用水配製如下:
加3ml配製成250mg/ml，可IM;
加10ml配製成90mg/ml，可IV推;
上述再加入其他輸液，可IV滴。
IV滴，30min以上;IV推，3-5 min
配製後2~8℃可放7天
配製後室溫可放18小時(生達)
|
針劑相容溶液
*為文獻資料 |
G5W, N.S., suntose, G5S, G10W, L-R*, 0.45% NaCl*
| 途徑 | 溶解液 | 溶解液量(ml) | 溶解後總量(ml) | | IM | Water for inj. (20ml/A) 針. | 3.00 | 4.00 | | IV推 | Water for inj. (20ml/A) 針. | 10.00 | 11.10 | | IV滴 | Water for inj. (20ml/A) 針. | 10.00 | 11.10 |
|
| 健保給付規定 |
藥品說明：
1)fluoroquinolone類若使用於結核病不予給付2)門診使用抗微生物製劑以不超過3日為原則,7日為限;慢性骨髓炎病患得視病情需要延長給藥日數,每次14日為上限 3)若微生物培養證明第一線抗微生物製劑有效,應考慮改用第一線抗微生物製劑 4)使用抗微生物製劑,宜以同療效,價廉為原則.
藥品理由：
01 合乎健保之給付病情,需直接使用第一線以外抗生素正進行菌種培養,請說明病情理由.
02 一線抗生素藥物敏感報告有效,仍需使用2,3線抗生素者,請說明理由.
03 已使用一線抗生素超過72 hrs, 且藥物敏感性試驗對第一線抗生素具抗藥性.
04 已於本院或其他醫院使用不同之一線抗生素7日以上仍無效者.
05 嬰幼兒(2m - 5yrs),患疑似感染疾病,在使用一線抗生素72小時仍無效者.
06 Ceftriaxone用於疑似或證實為淋病尿道炎、子宮頸炎、軟性下疳時，可第一線單一劑量使用。
07 Cefixime用於疑似或證實為淋病尿道炎、子宮頸炎、軟性下疳時，可第一線單一劑量使用。
08 感染高風險之免疫不全病人預防使用
|
舊藥品外觀
|
中文名：信騰注射劑
廠 牌：信東
|